Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are FTD disorders that primarily affect movement and are sometimes called atypical parkinsonism. In this Perspectives in FTD Research Webinar, presented jointly by AFTD and the FTD Disorders Registry, Dr. Anne-Marie Wills, director of the CurePSP Center of Care at Massachusetts General Hospital, will explore what PSP and CBS are and how research into these disorders is improving our scientific understanding. This webinar will also cover current clinical trial opportunities, and how people interested in participating can find out more.
This Perspectives in Research Webinar is made possible through the generous support of Alector.
Viewers will be able to:
Understand how PSP and CBS fit into the FTD umbrella.
Identify available clinical trials for PSP and CBS and what steps to take if they are interested in enrollment.
Understand why participating in PSP/CBS research matters.
DAY: Wednesday, November 15 TIME: 3 p.m. ET (noon PT) DURATION: Approximately 60 minutes
This event will accommodate up to 500 attendees, but pre-registration is required and will be honored on a first-come, first-served basis. Be sure to secure your spot today!
Unable to attend on this day and time? Not to worry. The presentation will be recorded and archived on our website within one week of broadcast.
Anne-Marie Wills, MD, MPH
Anne-Marie Wills, MD, MPH, is a neurologist specializing in neurodegenerative disease, such as Parkinson's Disease, Progressive Supranuclear Palsy (PSP), and ALS. She received her BA from Princeton University, her MD from Columbia College Physicians & Surgeons, and her MPH from Harvard School of Public Health. She completed her specialty training in the Mass General Brigham Neurology residency program, a combined program between Massachusetts General Hospital and Brigham and Women's Hospital. She has been on staff at Mass General since 2006. Currently, Dr. Wills is the director of the CurePSP Center of Care at MGH, which provides multidisciplinary care for people with progressive supranuclear palsy.